Immuron (IMRN) Asset Utilization Ratio (2018 - 2024)
Immuron (IMRN) recorded quarterly Asset Utilization Ratio of 643857203153.26 in Q4 2024, down 154820849854291.44% quarter-over-quarter from 0.42 in Q4 2023, and down 154820849854291.44% on a YoY basis from N/an in Q1 2024.
Immuron (IMRN) Asset Utilization Ratio (2018 - 2024) Analysis & Trends
Immuron's Asset Utilization Ratio history runs 7 years deep, the most recent figure standing at 643857203153.26 for Q4 2024.
- In Q4 2024, Asset Utilization Ratio fell 154820849854291.44% year-over-year to 643857203153.26; the TTM figure through Dec 2024 stood at 643857203153.26 (down 154820849854291.44% YoY), while the FY2025 annual figure was 1.41, up 557.39% from the prior year.
- Asset Utilization Ratio was 643857203153.26 for Q4 2024 at Immuron, down from 0.42 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.42 in Q4 2023 to a low of 643857203153.26 in Q4 2024.
- Historically, Asset Utilization Ratio has averaged 107309533858.77 across 5 years, with a median of 0.06 in 2020.
- The sharpest annual moves came in 2023 and 2024: Asset Utilization Ratio soared 1063.25% in 2023, then tumbled 154820849854291.44% in 2024.
- A 5-year view of Asset Utilization Ratio shows it stood at 0.07 in 2020, then soared by 41.12% to 0.09 in 2021, then plunged by 62.26% to 0.04 in 2022, then jumped by 1063.25% to 0.42 in 2023, then sank by 154820849854291.44% to 643857203153.26 in 2024.
- The last three Asset Utilization Ratio figures came in at 643857203153.26 (Q4 2024), 0.42 (Q4 2023), and 0.04 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 0.55 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.60 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 1,422.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Immuron | 921.61 Mn | 921.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -643.86 Bn |
| Dec 31, 2023 | 0.42 |
| Jun 30, 2023 | 0.04 |
| Dec 31, 2022 | 0.04 |
| Dec 31, 2021 | 0.09 |
| Dec 31, 2020 | 0.07 |
| Dec 31, 2019 | 0.74 |
| Dec 31, 2018 | 0.16 |